287 related articles for article (PubMed ID: 27178737)
1. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.
Hu Y; Liu J; Zhang H; Xu Y; Hong T; Wang G
Diabetes Metab; 2016 Nov; 42(5):358-363. PubMed ID: 27178737
[TBL] [Abstract][Full Text] [Related]
2. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Samson SL; Sathyanarayana P; Jogi M; Gonzalez EV; Gutierrez A; Krishnamurthy R; Muthupillai R; Chan L; Bajaj M
Diabetologia; 2011 Dec; 54(12):3093-100. PubMed ID: 21956711
[TBL] [Abstract][Full Text] [Related]
3. Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
Li X; Wu X; Jia Y; Fu J; Zhang L; Jiang T; Liu J; Wang G
J Diabetes Res; 2021; 2021():3715026. PubMed ID: 34660809
[TBL] [Abstract][Full Text] [Related]
4. Exenatide treatment increases serum irisin levels in patients with obesity and newly diagnosed type 2 diabetes.
Liu J; Hu Y; Zhang H; Xu Y; Wang G
J Diabetes Complications; 2016; 30(8):1555-1559. PubMed ID: 27503404
[TBL] [Abstract][Full Text] [Related]
5. High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes.
Yang K; Wang H; Wei R; Xiao W; Tian Q; Wang C; Yang J; Hong T
Acta Diabetol; 2021 May; 58(5):595-602. PubMed ID: 33452595
[TBL] [Abstract][Full Text] [Related]
6. FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
Samms RJ; Cheng CC; Fourcaudot M; Heikkinen S; Khattab A; Adams J; Cersosimo E; Triplitt C; Puckett C; Tsintzas K; Adams AC; Abdul-Ghani MA; DeFronzo RA; Norton L
Am J Physiol Endocrinol Metab; 2022 Aug; 323(2):E123-E132. PubMed ID: 35723225
[TBL] [Abstract][Full Text] [Related]
7. Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes.
Fan H; Sun X; Zhang H; Liu J; Zhang P; Xu Y; Pan Q; Wang G
Diabetes Technol Ther; 2016 Mar; 18(3):120-6. PubMed ID: 26950284
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Circulating Fibroblast Growth Factor 21 in Subjects with and without Type 2 Diabetes.
Lu J; Yu H; Mo Y; Ma X; Hao Y; Lu W; Li H; Bao Y; Zhou J; Jia W
PLoS One; 2015; 10(11):e0142207. PubMed ID: 26540514
[TBL] [Abstract][Full Text] [Related]
9. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P
Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033
[TBL] [Abstract][Full Text] [Related]
10. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus.
Li K; Li L; Yang M; Zong H; Liu H; Yang G
Eur J Endocrinol; 2009 Sep; 161(3):391-5. PubMed ID: 19528204
[TBL] [Abstract][Full Text] [Related]
11. Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial.
Kang C; Qiao Q; Tong Q; Bai Q; Huang C; Fan R; Wang H; Kaliannan K; Wang J; Xu J
Sci Rep; 2021 Oct; 11(1):20062. PubMed ID: 34625598
[TBL] [Abstract][Full Text] [Related]
12. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
[TBL] [Abstract][Full Text] [Related]
13. HOMA-S is associated with greater HbA1c reduction with a GLP-1 analogue in patients with type 2 diabetes.
Heald AH; Narayanan RP; Lowes D; Jarman E; Onyekwelu E; Qureshi Z; Laing I; Anderson SG
Exp Clin Endocrinol Diabetes; 2012 Jul; 120(7):420-3. PubMed ID: 22639398
[TBL] [Abstract][Full Text] [Related]
14. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
15. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
18. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
20. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
van Genugten RE; van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
